Phathom Pharmaceuticals Inc
NASDAQ:PHAT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Phathom Pharmaceuticals Inc
Cash & Cash Equivalents
Phathom Pharmaceuticals Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
|
Cash & Cash Equivalents
$130m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash & Cash Equivalents
$9.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
16%
|
CAGR 10-Years
-4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash & Cash Equivalents
$10.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
16%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash & Cash Equivalents
$1.1B
|
CAGR 3-Years
40%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-11%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash & Cash Equivalents
$14.6B
|
CAGR 3-Years
5%
|
CAGR 5-Years
13%
|
CAGR 10-Years
6%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash & Cash Equivalents
$7.3B
|
CAGR 3-Years
52%
|
CAGR 5-Years
15%
|
CAGR 10-Years
7%
|
|
Phathom Pharmaceuticals Inc
Glance View
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 77 full-time employees. The company went IPO on 2019-10-25. The Company’s pipeline product candidate, vonoprazan is an oral small molecule potassium-competitive acid blocker (P-CAB). P-CABs are a class of medicines that block acid secretion in the stomach. Vonoprazan has an anti-secretory effect and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease (GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
See Also
What is Phathom Pharmaceuticals Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
130m
USD
Based on the financial report for Dec 31, 2025, Phathom Pharmaceuticals Inc's Cash & Cash Equivalents amounts to 130m USD.
What is Phathom Pharmaceuticals Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-15%
Over the last year, the Cash & Cash Equivalents growth was -56%. The average annual Cash & Cash Equivalents growth rates for Phathom Pharmaceuticals Inc have been -6% over the past three years , -15% over the past five years .
